Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate

Authors Chandrasekar PH

Published 5 December 2008 Volume 2008:4(6) Pages 1285—1294

DOI https://doi.org/10.2147/TCRM.S1554

PH Chandrasekar

Division of Infectious Diseases, Department of Internal Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA

Abstract: Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective broad-spectrum drug in the treatment of invasive fungal infections in patients with infection refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has not been rigorously evaluated for primary therapy. Recent availability of several newer potent and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB lipid complex is likely to continue to play a limited albeit significant clinical role in view of the narrow spectrum of activity and significant drug-drug interactions of the newer drugs and emergence of drug-resistant fungi.

Keywords: amphotericin B lipid complex, invasive fungal infections

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]